Abelacimab Cuts Bleeding Risk in AF Patients Regardless of Kidney Function: AZALEA-TIMI 71 Analysis
USA: A secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, recently published in JAMA Cardiology, has highlighted the potential safety benefits of abelacimab, a novel factor XI inhibitor, compared with rivaroxaban in patients with atrial fibrillation (AF). The findings suggest that abelacimab may offer a more favorable bleeding profile across varying levels of kidney […]